16 results found.

Hyperlipidemia Clinical Trial using PF-04950615; Placebo

Pfizer - Recruiting 18 years or older.
- A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events.
PF-04950615; Placebo

Hyperlipidemia Clinical Trial using Part A, Atorvastatin; Part A, Placebo (administered orally); Part B, Evolocumab; Part B, Placebo (administered orally); Part B, Ezetimibe; Part B, Placebo (administered subcutaneously); Part C, Evolocumab

Amgen - Recruiting 18 years to 80 years.
- A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects.
Part A, Atorvastatin; Part A, Placebo (administered orally); Part B, Evolocumab; Part B, Placebo (administered orally); Part B, Ezetimibe; Part B, Placebo (administered subcutaneously); Part C, Evolocumab

Essential Hypertension, or Hyperlipidemia Clinical Trial using Atorvastatin; Losartan; Placebo; HL-040XC

HanAll BioPharma Co., Ltd. - Recruiting 18 years to 80 years.
- A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia.
Atorvastatin; Losartan; Placebo; HL-040XC

Hyperlipidemia and Mixed Dyslipidemia Clinical Trial using evolocumab (AMG 145) and standard of care; Standard of care

Amgen - Recruiting 18 years to 85 years.
- A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145-2.
evolocumab (AMG 145) and standard of care; Standard of care

Hyperlipidemia, Hypercholesterolemia, or Dyslipidemia Clinical Trial

Ohio State University - Recruiting 18 years or older.
- An Observational Study Investigating Genetic Influences on Statin Plasma Concentrations in Adults Taking Atorvastatin, Simvastatin, or Lovastatin.

HbA1c Level Associated With Lipid Compositions Clinical Trial using Pitavastatin calcium 4mg; Pitavastatin calcium 2mg

JW Pharmaceutical - Recruiting 20 years to 70 years.
- Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4).
Pitavastatin calcium 4mg; Pitavastatin calcium 2mg

Hyperlipidemia Clinical Trial using Capros dietary supplement

Ohio State University - Recruiting 21 years to 70 years.
- Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans.
Capros dietary supplement

Cardiovascular Disease, Hypertension, Diabetes, or Hyperlipidemia Clinical Trial using Pharmacist CVD

Department of Veterans Affairs - Recruiting N/A or older.
- Cardiovascular Intervention Improvement Telemedicine Study.
Pharmacist CVD

Hyperlipidemia, Hyperlipoproteinemia, or Hypolipoproteinemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Teaching Protocol for the Evaluation of Plasma Lipoproteins.

Hyperlipidemia, Familial Combined Clinical Trial using Atorvastatin 20mg; Omega-3-acids ethylesters 90 4g; Placebo(Omega-3-acids ethylesters 90)

Kuhnil Pharmaceutical Co., Ltd. - Recruiting 20 years to 80 years.
- A Randomized. Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Combination Therapy of Omega-3-acids Ethylesters 90/Atorvastatin Calcium in Type ?b Hyperlipidemia.
Atorvastatin 20mg; Omega-3-acids ethylesters 90 4g; Placebo(Omega-3-acids ethylesters 90)

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascu Clinical Trial using Statin; Placebo; Study Drug

Amgen - Recruiting 20 years to 85 years.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia.
Statin; Placebo; Study Drug

Hyperlipidemia, or Hypertension Clinical Trial using YH16410; Rosuvastatin; Telmisartan; YH16410 placebo; Rosuvastatin placebo; Telmisartan placebo

Yuhan Corporation - Recruiting 19 years or older.
- A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia.
YH16410; Rosuvastatin; Telmisartan; YH16410 placebo; Rosuvastatin placebo; Telmisartan placebo

Mixed Hyperlipidemia Clinical Trial using Atorvastatin 20mg; Fenofibrate 160mg; Placebo (Fenofibrate 160 mg)

Chong Kun Dang Pharmaceutical - Recruiting 19 years or older.
- Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study..
Atorvastatin 20mg; Fenofibrate 160mg; Placebo (Fenofibrate 160 mg)

Hyperlipidemia Clinical Trial using Bean powder; Rice bran

Poudre Valley Health System - Recruiting 8 years to 13 years.
- Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children Involved in the Healthy Hearts Program.
Bean powder; Rice bran

Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, or Hypert Clinical Trial using Etanercept

Massachusetts General Hospital - Recruiting 18 years or older.
- Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis.
Etanercept

Hyperlipidemia Clinical Trial using Omega-3 fatty acid (Eicosapentaenoic acid)

University of California, San Francisco - Recruiting 8 years to 17 years.
- Endothelial Assessment of Risk From Lipids in Youth: Mediterranean Diet.
Omega-3 fatty acid (Eicosapentaenoic acid)